Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial
Beneficial Microbes · 11.10.2021 · 12 (5) · 431-440
DOI: 10.3920/bm2020.0185 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Beneficial Microbes, erschienen am 11.10.2021. Verfasst von I Garaiova und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Department, Cultech Ltd, Unit 2 Christchurch Road, Port Talbot, SA12 7BZ, United Kingdom. Hauptthemen laut MEDLINE: Probiotics, Respiratory Tract Infections. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
In a double-blind, randomised, parallel-group, placebo-controlled study, healthy school children aged 3-10 years received a probiotic based supplement daily for 6 months to assess the impact on the incidence and duration of upper respiratory tract infection (URTI) symptoms. The intervention comprised Lab4 probiotic ( Lactobacillus acidophilus CUL21 and CUL60, Bifidobacterium bifidum CUL20 and Bifidobacterium animalis subsp . lactis CUL34) at 12.5 billion cfu/day plus 50 mg vitamin C or a matching placebo. 171 children were included in the analysis (85 in placebo and 86 in active group). Incidence of coughing was 16% ( P =0.0300) significantly lower in the children receiving the active intervention compared to the placebo. No significant differences in the incidence rate of other URTI symptoms were observed. There was significantly lower risk of experiencing five different URTI related symptoms in one day favouring the active group (Risk ratio: 0.31, 95% confidence interval: 0.12, 0.81, P =0.0163). Absenteeism from school and the use of antibiotics was also significantly reduced for those in the active group (-16%, P =0.0060 and -27%, P =0.0203, respectively). Our findings indicate that six months daily supplementation with the Lab4 probiotic and vitamin C combination reduces the incidence of coughing, absenteeism and antibiotic usage in 3 to 10 year old children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development Department, Cultech Ltd, Unit 2 Christchurch Road, Port Talbot, SA12 7BZ, United Kingdom.
- Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia.
- JuvenaliaA Paediatric Centre, Veľkoblahovská 44/A, 929 01 Dunajská Streda, Slovakia.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, United Kingdom.
- School of Biosciences, Cardiff University, Cardiff, CF10 3AX, United Kingdom.
- Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, W2 1NY, United Kingdom.
Zitieren
APA
Garaiova, I., Paduchová, Z., Nagyová, Z., Wang, D., Michael, D. R., Plummer, S. F., Marchesi, J. R., Ďuračková, Z., & Muchová, J. (2021). Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial. Beneficial Microbes, 12(5), 431-440. https://doi.org/10.3920/bm2020.0185
Vancouver
Garaiova I, Paduchová Z, Nagyová Z, Wang D, Michael DR, Plummer SF, et al. Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial. Beneficial Microbes. 2021;12(5):431-440. doi:10.3920/bm2020.0185
BibTeX
@article{Garaiova2021,
author = {Garaiova, I and Paduchová, Z and Nagyová, Z and Wang, D and Michael, D R and Plummer, S F and Marchesi, J R and Ďuračková, Z and Muchová, J},
title = {Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial},
journal = {Beneficial Microbes},
year = {2021},
volume = {12},
number = {5},
pages = {431--440},
doi = {10.3920/bm2020.0185}
}
EUVIMED